Recent developments in animal venom peptide nanotherapeutics with improved selectivity for cancer cells

Giribaldi, Julien; Smith, Jennifer J.; Schroeder, Christina I.

doi:10.1016/j.biotechadv.2021.107769

Cited by 17 publications

(11 citation statements)

References 278 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One is their pharmacology. To confine their action just on malignant cells, they have to be delivered precisely to the tumor ( 101 ), in our case to GB, more desirable specifically to GSCs. The other problem is their complexity and size.…”

Section: Discussion: Limitations and Challengesmentioning

confidence: 99%

“…So far, only two peptides targeting VGCCs have been tested on GB. PnTx3-6 (also Phα1β), a peptide from the venom of the wandering spider ( Phoneutria nigriventer ), is a VGCC blocker with a characteristic ICK structural motif ( 101 ). Without being toxic, it exhibited potent analgesic effect in rat models of inflammatory and neuropathic pain as well as an anti-nociceptive effect ( 20 ).…”

Section: Molecular Background Of Action Of Venom Peptides On Glioblas...mentioning

confidence: 99%

See 1 more Smart Citation

Bioactive peptides from venoms against glioma progression

et al. 2022

View full text Add to dashboard Cite

Venoms are complex mixtures of different molecules and ions. Among them, bioactive peptides have been found to affect cancer hallmarks, such as cell proliferation, cell invasion, cell migration, and can also modulate the immune response of normal and cancer-bearing organisms. In this article, we review the mechanisms of action on these cancer cell features, focusing on bioactive peptides being developed as potential therapeutics for one of the most aggressive and deadly brain tumors, glioblastoma (GB). Novel therapeutic approaches applying bioactive peptides may contribute to multiple targeting of GB and particularly of GB stem cells. Bioactive peptides selectively target cancer cells without harming normal cells. Various molecular targets related to the effects of bioactive peptides on GB have been proposed, including ion channels, integrins, membrane phospholipids and even immunomodulatory treatment of GB. In addition to therapy, some bioactive peptides, such as disintegrins, can also be used for diagnostics or are used as labels for cytotoxic drugs to specifically target cancer cells. Given the limitations described in the last section, successful application in cancer therapy is rather low, as only 3.4% of such peptides have been included in clinical trials and have passed successfully phases I to III. Combined approaches of added bioactive peptides to standard cancer therapies need to be explored using advanced GB in vitro models such as organoids. On the other hand, new methods are also being developed to improve translation from research to practice and provide new hope for GB patients and their families.

show abstract

Section: Discussion: Limitations and Challengesmentioning

confidence: 99%

Section: Molecular Background Of Action Of Venom Peptides On Glioblas...mentioning

confidence: 99%

Bioactive peptides from venoms against glioma progression

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Nanostructures have been utilized as vehicles intended to protect the peptides from enzymatic degradation or denaturation and prevent their release until they reach the site of action, giving larger specificity of molecules towards their targets. Furthermore, nanoscale materials have a large specific surface area, flexible surface functionalization, and some physicochemical properties that could be exploited to improve the molecule druggability [ 161 ].…”

Section: Prospects and Challengesmentioning

confidence: 99%

Nanobiotechnology with Therapeutically Relevant Macromolecules from Animal Venoms: Venoms, Toxins, and Antimicrobial Peptides

et al. 2022

View full text Add to dashboard Cite

Some diseases of uncontrolled proliferation such as cancer, as well as infectious diseases, are the main cause of death in the world, and their causative agents have rapidly developed resistance to the various existing treatments, making them even more dangerous. Thereby, the discovery of new therapeutic agents is a challenge promoted by the World Health Organization (WHO). Biomacromolecules, isolated or synthesized from a natural template, have therapeutic properties which have not yet been fully studied, and represent an unexplored potential in the search for new drugs. These substances, starting from conglomerates of proteins and other substances such as animal venoms, or from minor substances such as bioactive peptides, help fight diseases or counteract harmful effects. The high effectiveness of these biomacromolecules makes them promising substances for obtaining new drugs; however, their low bioavailability or stability in biological systems is a challenge to be overcome in the coming years with the help of nanotechnology. The objective of this review article is to describe the relationship between the structure and function of biomacromolecules of animal origin that have applications already described using nanotechnology and targeted delivery.

show abstract

“…At present, there have been many explorations and modifications of p53-activator peptides, and considerable therapeutic effects have been achieved at the animal level Yan et al, 2021). However, searching for higheraffinity peptide segments and overcoming their pharmacological barriers (Giribaldi et al, 2021;Gonzalez-Valdivieso et al, 2021) to promote their clinical translation still have a long way to go. Supramolecular polymers, different from traditional chemistry molecules, are based on non-covalent interactions between molecules, such as metal coordination and hydrogen bonding, and are attracting increasing attention as nano-drugs (Aida et al, 2012;Zhou et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

“…At present, there have been many explorations and modifications of p53-activator peptides, and considerable therapeutic effects have been achieved at the animal level ( Zheng et al, 2021 ; Yan et al, 2021 ). However, searching for higher-affinity peptide segments and overcoming their pharmacological barriers ( Giribaldi et al, 2021 ; Gonzalez-Valdivieso et al, 2021 ) to promote their clinical translation still have a long way to go.…”

Section: Introductionmentioning

confidence: 99%

Assembling p53 Activating Peptide With CeO2 Nanoparticle to Construct a Metallo-Organic Supermolecule Toward the Synergistic Ferroptosis of Tumor

Wang

He²,

Zhang³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Inducing lipid peroxidation and subsequent ferroptosis in cancer cells provides a potential approach for anticancer therapy. However, the clinical translation of such therapeutic agents is often hampered by ferroptosis resistance and acquired drug tolerance in host cells. Emerging nanoplatform-based cascade engineering and ferroptosis sensitization by p53 provides a viable rescue strategy. Herein, a metallo-organic supramolecular (Nano-PMI@CeO2) toward p53 restoration and subsequent synergistic ferroptosis is constructed, in which the radical generating module-CeO2 nanoparticles act as the core, and p53-activator peptide (PMI)-gold precursor polymer is in situ reduced and assembled on the CeO2 surface as the shell. As expected, Nano-PMI@CeO2 effectively reactivated the p53 signaling pathway in vitro and in vivo, thereby downregulating its downstream gene GPX4. As a result, Nano-PMI@CeO2 significantly inhibited tumor progression in the lung cancer allograft model through p53 restoration and sensitized ferroptosis, while maintaining favorable biosafety. Collectively, this work develops a tumor therapeutic with dual functions of inducing ferroptosis and activating p53, demonstrating a potentially viable therapeutic paradigm for sensitizing ferroptosis via p53 activation. It also suggests that metallo-organic supramolecule holds great promise in transforming nanomedicine and treating human diseases.

show abstract

Recent developments in animal venom peptide nanotherapeutics with improved selectivity for cancer cells

Cited by 17 publications

References 278 publications

Bioactive peptides from venoms against glioma progression

Bioactive peptides from venoms against glioma progression

Nanobiotechnology with Therapeutically Relevant Macromolecules from Animal Venoms: Venoms, Toxins, and Antimicrobial Peptides

Assembling p53 Activating Peptide With CeO2 Nanoparticle to Construct a Metallo-Organic Supermolecule Toward the Synergistic Ferroptosis of Tumor

Contact Info

Product

Resources

About